The former is a highly selective allosteric inhibitor of Mek1/2 that has entered clinical trials for several solid tumors [16,17,18], while trametinib is the first FDA-approved MEK1/2 inhibitor currently in use for unresectable and metastatic melanoma. This evidence concerns the gene MAP2K1 and metastatic melanoma.